The TRANSCEND Study is a prospective, multi-center, double-blind, randomized, controlled clinical trial. It aims to study the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using the Abbott Infinity Deep Brain Stimulation (DBS) system as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) for adults who are experiencing a Major Depressive Episode (MDE) with inadequate response to 4 or more antidepressant treatments.
A recent analysis of five prior studies of stimulation of the SgCwm pooled 172 subjects and analyzed long-term response rates. Average MADRS reduction at 24-months post-device activation was 53% with response rates of 55%. In light of these promising long-term analyses the TRANSCEND Study was launched.
At Beth Israel Deaconess Medical Center Dr. Aronson serves as site primary investigator. Dr. Roscoe Brady and Dr. Subha Subramanian in the Department of Psychiatry serve as co-investigators.
If you are interested in learning more about the TRANSCEND Study at BIDMC please contact Domenic Anand.